Actively Recruiting

Phase Not Applicable
All Genders
ID01451502

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units for Lymphatic Diseases and Hematopoietic Malignancies

Led by Masonic Cancer Center, University of Minnesota · Updated on 2026-05-08

250

Participants Needed

1

Research Sites

21 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This research evaluates the use of unlicensed umbilical cord blood (UCB) units as a source of cells for treating lymphatic diseases and hematopoietic malignancies. The study acknowledges that for the next 5 to 10 years or longer, many cord blood units worldwide will remain unlicensed, but some may have attributes making them better suited for certain treatments. Access to unlicensed UCB units is important due to the wide variety of potential applications in cellular therapy and hematopoietic reconstitution. Patients receive pre-infusion treatments including intravenous hydration, acetaminophen, and diphenhydramine or suitable alternatives adjusted by age and weight about 30 minutes before the UCB infusion. The infusion involves minimally manipulated unlicensed UCB units delivered through a central line following institutional guidelines. Vital signs are monitored during and after infusion, and infusion reactions are managed as needed. Post-transplant care and follow-up are conducted according to disease-specific protocols and institutional standards. Participants are registered under this protocol and the specific treatment protocol for their condition. Researchers monitor the incidence of blood-borne pathogen transmission within 24 hours post-infusion, serious infusion reactions up to 180 days, cell counts in the UCB units before infusion, labeling errors, and compare outcomes from different cord blood banks. Follow-up care and evaluations continue according to the disease protocol. The study aims to ensure safety and track the use of unlicensed UCB units over time.

CONDITIONS

Brief Title

Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Diagnosis requiring umbilical cord blood as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution under an IRB-approved treatment protocol
  • Written informed consent provided for use of unlicensed UCB units and co-enrollment onto a University of Minnesota IRB-approved clinical trial
  • Availability of an unlicensed UCB unit meeting required cell dose and HLA matching criteria, negative for tested blood-borne pathogens, and no equivalent licensed UCB unit available
Not Eligible

You will not qualify if you...

  • Exclusion criteria are specified in the disease-specific treatment protocol according to indication

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Treatment

Duration - Single infusion event with immediate monitoring period

Participants receive pre-infusion treatment including intravenous hydration, acetaminophen, and diphenhydramine hydrochloride approximately 30 minutes prior to infusion. The unlicensed umbilical cord blood unit is then infused through a central line according to institutional guidelines with monitoring of vital signs during and after infusion and management of any infusion reactions.

1 infusion visit (in-person) with vital signs monitoring during and after infusion

Follow-up

Duration - Up to 180 days after infusion

Participants receive post-transplant care and follow-up according to disease-specific treatment protocols and institutional guidelines, including monitoring for infusion reactions and other outcomes.

Trial Site Locations

Total: 1 location

1

Masonic Cancer Center, University of Minnesota

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

OTHER

Number of Arms

1

Similar Trials

A Prospective Natural History Study of Lymphatic Anomalies

Lymphatic Diseases

Actively Recruiting

2 locations

A Clinical Study of Low-dose Total Body Irradiation and Flud...

Hematopoietic Malignancy

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here